We are laser-focused on our mission: to improve the lives of patients and their families.

Clinical Trials

Our pipeline programs target kidney diseases of high unmet need: ADPKD and Alport syndrome.

Programs

We are targeting the underlying biology of these diseases with a novel and potentially powerful approach: MicroRNA-based therapeutics.

Technology

News.

June 21, 2022

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

June 13, 2022

Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

June 2, 2022

Regulus Appoints Amin Kamel, Ph.D., as Vice President, DMPK

MORE NEWS